PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-46.12%
Negative net income growth while AVGO stands at 12.35%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
8.09%
Some D&A expansion while AVGO is negative at -15.13%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-140.89%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
4.90%
SBC growth well above AVGO's 1.03%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-143.00%
Both reduce yoy usage, with AVGO at -64.59%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-13.87%
Both yoy AR lines negative, with AVGO at -14.52%. Martin Whitman would suspect an overall sector lean approach or softer demand.
-49.73%
Negative yoy inventory while AVGO is 129.89%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
39.34%
A yoy AP increase while AVGO is negative at -126.32%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-373.04%
Negative yoy usage while AVGO is 23.71%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
1782.43%
Some yoy increase while AVGO is negative at -111.11%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-42.93%
Both yoy CFO lines are negative, with AVGO at -11.94%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-32.23%
Negative yoy CapEx while AVGO is 15.57%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
40.00%
Less M&A spending yoy vs. AVGO's 100.00%, reducing near-term risk. David Dodd would confirm the firm is not missing out on a strategic deal that competitor might exploit.
54.81%
Purchases growth of 54.81% while AVGO is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-7.28%
We reduce yoy sales while AVGO is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-250.00%
Both yoy lines negative, with AVGO at -100.00%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
264.59%
Investing outflow well above AVGO's 19.53%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
97.82%
We repay more while AVGO is negative at -2788.89%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-100.00%
Both yoy lines negative, with AVGO at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
-220.90%
Both yoy lines negative, with AVGO at -455.11%. Martin Whitman would see an overall reduced environment for buybacks in the niche or cyclical factor driving capital usage.